Preliminary results with administration of recombinant human erythropoietin in sickle cell/beta-thalassemia patients during pregnancy. (abre uma nova janela)

Bourantas K, Makrydimas G, Georgiou J, Tsiara S, Lolis D.

Fonte‎: Eur J Haematol 1996;56(5):326-8.

Indexado‎: PubMed 8641410

https://www.ncbi.nlm.nih.gov/pubmed/8641410 (abre uma nova janela)

On the use of hydroxyurea/erythropoietin combination therapy for sickle cell disease. (abre uma nova janela)

el-Hazmi MA, al-Momen A, Kandaswamy S, Huraib S, Harakati M, al-Mohareb F, Warsy AS.

Fonte‎: Acta Haematol 1995;94(3):128-34.

Indexado‎: PubMed 7502628

https://www.ncbi.nlm.nih.gov/pubmed/7502628 (abre uma nova janela)

Combination erythropoietin-hydroxyurea therapy in sickle cell disease: experience from the National Institutes of Health and a literature review. (abre uma nova janela)

Little JA, McGowan VR, Kato GJ, Partovi KS, Feld JJ, Maric I, Martyr S, Taylor JG 6th, Machado RF, Heller T, Castro O, Gladwin MT.

Fonte‎: Haematologica 2006;91(8):1076-83.

Indexado‎: PubMed 16885048

https://www.ncbi.nlm.nih.gov/pubmed/16885048 (abre uma nova janela)

Use of erythropoietin in a pregnant Jehovah's Witness with sickle-cell disease. (abre uma nova janela)

Tan TL, Ahmad H, Jhavar R, Patel R, Harrison C, Oteng-Ntim E.

Fonte‎: J Obstet Gynaecol 2007;27(1):82-3.

Indexado‎: PubMed 17365469

DOI‎: 10.1080/01443610601062739

https://www.ncbi.nlm.nih.gov/pubmed/17365469 (abre uma nova janela)

The use of barbiturate coma as salvage therapy in a postoperative Jehovah's Witness patient with life-threatening anemia. (abre uma nova janela)

Wang SW, Badami CD, Deitch EA.

Fonte‎: Am Surg 2009;75(12):1175-8.

Indexado‎: PubMed 19999907

https://www.ncbi.nlm.nih.gov/pubmed/19999907 (abre uma nova janela)